Garmezy, Benjamin
Sarah Cannon · Tennessee Oncology
2 papers on CoChatORCID 0000-0003-2790-6235
Most cited papers
- Verified
Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)
Iyer, G., Siefker-Radtke, A., Milowsky, M., Shore, N., Gao, X., Reimers, M. A., Hahn, N., Cosman, R., Matsubara, N., Necchi, A., et al. (2023) · Cancer Research
Fibroblast Growth Factor ResearchLung Cancer Treatments and Mutations
Cited by 12
- Verified
ARC-20: a Phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2α inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors
Choueiri, T. K., Garmezy, B., Paterson, E., Ghasemi, M., Cheng, T., Foster, P. G., Hauke, R. J., & Patnaik, A. (2023) · Journal of Clinical Oncology
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 5
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free